Compare Heron Therapeutics Inc (HRTX) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Msci Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Msci Inc trades at $562.19 (market cap $40.38B). The key difference: Msci Inc is far larger — about 593.7× Heron Therapeutics Inc's market cap, and Msci Inc pays a 1.48% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Msci Inc for 82 Days on average.
| HRTX | MSCI | |
|---|---|---|
Market Cap | $68.01M | $40.38B |
Volume | 1,891,941 | 414,140 |
Sector | Health | Financials |
52-Week High | $1.49 | $643.83 |
52-Week Low | $0.27 | $511.84 |
Typical Hold Time | 35 Days | 82 Days |
Enterprise Value | $174.75M | $46.54B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
MSCI trades at $555.38, up 0.08% on the day, with a neutral technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed slightly. Analyst sentiment is bullish with a 74% buy rating and a $701.71 consensus price target, suggesting significant upside. The company maintains robust cash flow from operations at $1.59B in 2025.
Outlook remains positive due to high profitability and analyst confidence, but risks include elevated valuation multiples and high long-term debt of $4.51B. The upcoming Q3 2026 earnings call on October 20, 2026, will be a key catalyst. Investors should weigh the strong growth trajectory against debt levels and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
